vs
NATIONAL FUEL GAS CO（NFG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是NATIONAL FUEL GAS CO的1.8倍（$772.1M vs $425.9M），NATIONAL FUEL GAS CO净利率更高（35.7% vs 12.7%，领先23.0%），Revvity同比增速更快（5.9% vs 1.7%），过去两年NATIONAL FUEL GAS CO的营收复合增速更高（12.1% vs 9.0%）
该多元化能源企业成立于1902年，总部位于美国纽约州威廉斯维尔，总资产达62亿美元，下设勘探与生产、管道与存储、燃气集输、公用事业、能源营销五大运营板块，业务覆盖能源产业链上下游多个核心环节。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
NFG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$425.9M
营收增速更快
RVTY
高出4.1%
1.7%
净利率更高
NFG
高出23.0%
12.7%
两年增速更快
NFG
近两年复合增速
9.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $425.9M | $772.1M |
| 净利润 | $152.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 81.5% | 14.5% |
| 净利率 | 35.7% | 12.7% |
| 营收同比 | 1.7% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $1.59 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NFGRVTY
| Q1 26 | $425.9M | — | ||
| Q4 25 | $637.9M | $772.1M | ||
| Q3 25 | $443.1M | $698.9M | ||
| Q2 25 | $527.4M | $720.3M | ||
| Q1 25 | $734.8M | $664.8M | ||
| Q4 24 | $513.8M | $729.4M | ||
| Q3 24 | $310.0M | $684.0M | ||
| Q2 24 | $338.6M | $691.7M |
净利润NFGRVTY
| Q1 26 | $152.0M | — | ||
| Q4 25 | $181.6M | $98.4M | ||
| Q3 25 | $107.3M | $46.7M | ||
| Q2 25 | $149.8M | $53.9M | ||
| Q1 25 | $216.4M | $42.2M | ||
| Q4 24 | $45.0M | $94.6M | ||
| Q3 24 | $-167.6M | $94.4M | ||
| Q2 24 | $-54.2M | $55.4M |
毛利率NFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | 86.6% | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | 94.7% | 54.5% | ||
| Q1 25 | 81.6% | 56.5% | ||
| Q4 24 | 87.3% | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | 98.5% | 55.7% |
营业利润率NFGRVTY
| Q1 26 | 81.5% | — | ||
| Q4 25 | 43.3% | 14.5% | ||
| Q3 25 | 40.6% | 11.7% | ||
| Q2 25 | 43.7% | 12.6% | ||
| Q1 25 | 43.2% | 10.9% | ||
| Q4 24 | 16.8% | 16.3% | ||
| Q3 24 | -63.4% | 14.3% | ||
| Q2 24 | -15.2% | 12.4% |
净利率NFGRVTY
| Q1 26 | 35.7% | — | ||
| Q4 25 | 28.5% | 12.7% | ||
| Q3 25 | 24.2% | 6.7% | ||
| Q2 25 | 28.4% | 7.5% | ||
| Q1 25 | 29.4% | 6.4% | ||
| Q4 24 | 8.8% | 13.0% | ||
| Q3 24 | -54.1% | 13.8% | ||
| Q2 24 | -16.0% | 8.0% |
每股收益（稀释后）NFGRVTY
| Q1 26 | $1.59 | — | ||
| Q4 25 | $1.98 | $0.86 | ||
| Q3 25 | $1.18 | $0.40 | ||
| Q2 25 | $1.64 | $0.46 | ||
| Q1 25 | $2.37 | $0.35 | ||
| Q4 24 | $0.49 | $0.77 | ||
| Q3 24 | $-1.81 | $0.77 | ||
| Q2 24 | $-0.59 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $300.0M | — |
| 股东权益账面价值 | — | $7.3B |
| 总资产 | $9.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $271.4M | $919.9M | ||
| Q3 25 | $43.2M | $931.4M | ||
| Q2 25 | $39.3M | $991.8M | ||
| Q1 25 | $40.0M | $1.1B | ||
| Q4 24 | $48.7M | $1.2B | ||
| Q3 24 | $38.2M | $1.2B | ||
| Q2 24 | $81.4M | $2.0B |
总债务NFGRVTY
| Q1 26 | $300.0M | — | ||
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.7B | — | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.7B | — |
股东权益NFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $3.6B | $7.3B | ||
| Q3 25 | $3.1B | $7.4B | ||
| Q2 25 | $3.0B | $7.6B | ||
| Q1 25 | $2.8B | $7.6B | ||
| Q4 24 | $-76.2M | $7.7B | ||
| Q3 24 | $-15.5M | $7.9B | ||
| Q2 24 | $5.0M | $7.9B |
总资产NFGRVTY
| Q1 26 | $9.1B | — | ||
| Q4 25 | $9.2B | $12.2B | ||
| Q3 25 | $8.7B | $12.1B | ||
| Q2 25 | $8.4B | $12.4B | ||
| Q1 25 | $8.5B | $12.4B | ||
| Q4 24 | $8.3B | $12.4B | ||
| Q3 24 | $8.3B | $12.8B | ||
| Q2 24 | $8.5B | $13.4B |
负债/权益比NFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.99× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 532.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | 117.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 4.32× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流NFGRVTY
| Q1 26 | $657.3M | — | ||
| Q4 25 | $274.9M | $182.0M | ||
| Q3 25 | $237.8M | $138.5M | ||
| Q2 25 | $388.4M | $134.3M | ||
| Q1 25 | $253.8M | $128.2M | ||
| Q4 24 | $220.1M | $174.2M | ||
| Q3 24 | $197.9M | $147.9M | ||
| Q2 24 | $281.8M | $158.6M |
自由现金流NFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-2.7M | $161.8M | ||
| Q3 25 | $-47.8M | $120.0M | ||
| Q2 25 | $195.3M | $115.5M | ||
| Q1 25 | $59.9M | $112.2M | ||
| Q4 24 | $-20.3M | $149.8M | ||
| Q3 24 | $-49.1M | $125.6M | ||
| Q2 24 | $79.5M | $136.6M |
自由现金流率NFGRVTY
| Q1 26 | — | — | ||
| Q4 25 | -0.4% | 21.0% | ||
| Q3 25 | -10.8% | 17.2% | ||
| Q2 25 | 37.0% | 16.0% | ||
| Q1 25 | 8.2% | 16.9% | ||
| Q4 24 | -4.0% | 20.5% | ||
| Q3 24 | -15.8% | 18.4% | ||
| Q2 24 | 23.5% | 19.7% |
资本支出强度NFGRVTY
| Q1 26 | 117.0% | — | ||
| Q4 25 | 43.5% | 2.6% | ||
| Q3 25 | 64.4% | 2.6% | ||
| Q2 25 | 36.6% | 2.6% | ||
| Q1 25 | 26.4% | 2.4% | ||
| Q4 24 | 46.8% | 3.4% | ||
| Q3 24 | 79.7% | 3.3% | ||
| Q2 24 | 59.7% | 3.2% |
现金转化率NFGRVTY
| Q1 26 | 4.32× | — | ||
| Q4 25 | 1.51× | 1.85× | ||
| Q3 25 | 2.21× | 2.97× | ||
| Q2 25 | 2.59× | 2.49× | ||
| Q1 25 | 1.17× | 3.03× | ||
| Q4 24 | 4.89× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NFG
| Revenues from External Customers | $425.8M | 100% |
| Intersegment Revenues | $126.0K | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
